These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 36183413)
1. [Imipenem-cilastatin-relebactam used to treat ventilator-associated pneumonia developing after infection with SARS-CoV-2]. Zahornacký O; Porubčin Š; Rovňáková A; Jarčuška P Klin Mikrobiol Infekc Lek; 2022 Mar; 28(1):18-21. PubMed ID: 36183413 [TBL] [Abstract][Full Text] [Related]
2. Imipenem/cilastatin/relebactam: A new carbapenem β-lactamase inhibitor combination. Mansour H; Ouweini AEL; Chahine EB; Karaoui LR Am J Health Syst Pharm; 2021 Mar; 78(8):674-683. PubMed ID: 33580649 [TBL] [Abstract][Full Text] [Related]
3. An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date. Sellarès-Nadal J; Eremiev S; Burgos J; Almirante B Expert Opin Pharmacother; 2021 Aug; 22(12):1521-1531. PubMed ID: 34120547 [No Abstract] [Full Text] [Related]
4. Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections. Heo YA Drugs; 2021 Feb; 81(3):377-388. PubMed ID: 33630278 [TBL] [Abstract][Full Text] [Related]
5. New evidence in severe pneumonia: imipenem/ cilastatin/relebactam. Girón RM; Ibáñez A; Gómez-Punter RM; Alarcón T Rev Esp Quimioter; 2022 Apr; 35 Suppl 1(Suppl 1):46-49. PubMed ID: 35488826 [TBL] [Abstract][Full Text] [Related]
6. Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections. Smith JR; Rybak JM; Claeys KC Pharmacotherapy; 2020 Apr; 40(4):343-356. PubMed ID: 32060929 [TBL] [Abstract][Full Text] [Related]
7. Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres. Shields RK; Yücel E; Turzhitsky V; Merchant S; Min JS; Watanabe AH J Glob Antimicrob Resist; 2024 Jun; 37():190-194. PubMed ID: 38588973 [TBL] [Abstract][Full Text] [Related]
8. Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. Kaye KS; Boucher HW; Brown ML; Aggrey A; Khan I; Joeng HK; Tipping RW; Du J; Young K; Butterton JR; Paschke A Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094127 [TBL] [Abstract][Full Text] [Related]
9. Dynamic evolution of imipenem/relebactam resistance in a KPC-producing Klebsiella pneumoniae from a single patient during ceftazidime/avibactam-based treatments. Gaibani P; Bovo F; Bussini L; Lazzarotto T; Amadesi S; Bartoletti M; Viale P; Ambretti S J Antimicrob Chemother; 2022 May; 77(6):1570-1577. PubMed ID: 35373297 [TBL] [Abstract][Full Text] [Related]
10. Invitro activity of imipenem-relebactam against gram-negative bacilli isolated from patients with lower respiratory tract infections in the United States in 2015 - Results from the SMART global surveillance program. Lob SH; Hackel MA; Kazmierczak KM; Hoban DJ; Young K; Motyl MR; Karlowsky JA; Sahm DF Diagn Microbiol Infect Dis; 2017 Jun; 88(2):171-176. PubMed ID: 28291628 [TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Titov I; Wunderink RG; Roquilly A; Rodríguez Gonzalez D; David-Wang A; Boucher HW; Kaye KS; Losada MC; Du J; Tipping R; Rizk ML; Patel M; Brown ML; Young K; Kartsonis NA; Butterton JR; Paschke A; Chen LF Clin Infect Dis; 2021 Dec; 73(11):e4539-e4548. PubMed ID: 32785589 [TBL] [Abstract][Full Text] [Related]
12. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects. Rizk ML; Rhee EG; Jumes PA; Gotfried MH; Zhao T; Mangin E; Bi S; Chavez-Eng CM; Zhang Z; Butterton JR Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311084 [TBL] [Abstract][Full Text] [Related]
13. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations. Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684 [TBL] [Abstract][Full Text] [Related]
14. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections. Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669 [TBL] [Abstract][Full Text] [Related]
15. Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Sims M; Mariyanovski V; McLeroth P; Akers W; Lee YC; Brown ML; Du J; Pedley A; Kartsonis NA; Paschke A J Antimicrob Chemother; 2017 Sep; 72(9):2616-2626. PubMed ID: 28575389 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests. Jean SS; Hsieh TC; Hsu CW; Lee WS; Bai KJ; Lam C J Microbiol Immunol Infect; 2016 Dec; 49(6):924-933. PubMed ID: 26341302 [TBL] [Abstract][Full Text] [Related]